Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

10.68 -0.41 (-3.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know ↗
An SVB Leerink genetic medicine analyst is bullish on shares of Intellia Therapeutics, Inc. (NASDAQ: 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher ↗
Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Intellia Makes a Splash, Bringing Other CRISPR Stocks Along for the Ride ↗
Intellia's recent press release reveals first-of-its-kind clinical results for genome editing technology, leading NTLA stock skyward. 
Via InvestorPlace
News headline image
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money ↗
Find out why these stocks are climbing higher. 
Via The Motley Fool
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Intellia Therapeutics (NASDAQ:NTLA 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump ↗
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
Why Beam Therapeutics Jumped Today ↗
A first for CRISPR-Cas9 might signal a new phase in the gene-editing revolution. 
Via The Motley Fool
News headline image
Why Editas Medicine Stock Is Jumping Today ↗
Good news for Intellia was viewed as good news for Editas. 
Via The Motley Fool
News headline image
44 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
News headline image
Why Intellia Therapeutics Stock Is Skyrocketing Today ↗
The company reported promising interim trial results for its CRISPR gene-editing candidate. 
Via The Motley Fool
News headline image
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR ↗
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Highs On Monday ↗
During the morning session on Monday, 118 stocks hit new 52-week highs. Highlights: The company with the largest market cap to set a new 52-week high was Microsoft... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook ↗
Following the market opening Monday, the Dow traded down 0.30% to 34,329.01 while the NASDAQ rose 0.60% to 14,446.74. The S&P also rose, gaining 0.04% to 4,282.58. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
Why Intellia Therapeutics Stock Is Soaring Today ↗
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading signifi... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Barclays raised the price target for Accenture plc (NYSE: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion.... 
Via Benzinga
News headline image
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks ↗
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. 
Via InvestorPlace
News headline image
24 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
News headline image
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate ↗
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Mixed; Crude Oil Edges Lower ↗
Pre-open movers U.S. stock futures traded mixed in early pre-market trade after the Dow Jones surged more than 230 points in the previous session. The S&P 500 index also... 
Via Benzinga
Topics Stocks
News headline image
Expert Ratings For Intellia Therapeutics ↗
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1... 
Via Benzinga
News headline image
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company
From Blackstone
Via Business Wire
News headline image
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
News headline image
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021 ↗
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
News headline image
What's the Best Way to Invest in Genetics Stocks? ↗
Here are some of our experts' favorite gene editing plays for the long run. 
Via The Motley Fool
News headline image
This Genetics Stock Could Have a Bright Future ↗
Here's one genetics play that you might want to put on your radar. 
Via The Motley Fool
News headline image
Biotech Stocks Cruise Through The Volatility ↗
The XLV Healthcare Select SPDR is up 10% YTD. 
Via Talk Markets
News headline image
10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
News headline image
Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call Transcript ↗
NTLA earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.